IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
Condition: NSCLC Interventions: Biological: IO102; Biological: pembrolizumab (Keytruda); Drug: Carboplatin (Carboplatin Kabi); Drug: Pemetrexed (Pemetrexed Alvogen) Sponsors: IO Biotech; Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials